research

Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study

iRBD, Pre-PD /

Background:Prodromal multiple system atrophy (MSA) has been characterized mainly by retrospective chart reviews. Direct observation and tracking of prodromal markers in MSA have been very limited Objective:To report the baseline characteristics and evolution of prodromal markers of MSA as they were prospectively measured in patients with idiopathic/isolated REM sleep behavior disorder (iRBD) Methods:Patients with iRBD were […]

Evolution of Prodromal Multiple System Atrophy from REM Sleep Behavior Disorder: A Descriptive Study Read More »

Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson’s Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder

A-Synuclein, Probiotics, Prebiotics and Symbiotics /

This study aimed to evaluate the attenuating effect of Lactobacillus plantarum DP189 on α-synuclein (α-SYN) aggregates in the substantia nigra (SN) of Parkinson’s disease (PD) mice via 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced. Our results indicated that L. plantarum DP189 increased the levels of superoxide dismutase (SOD), glutathione peroxide (GSH-Px), and interleukin-10 (IL-10) and decreased the levels of malondialdehyde (MDA), reactive oxygen species

Lactobacillus plantarum DP189 Reduces α-SYN Aggravation in MPTP-Induced Parkinson’s Disease Mice via Regulating Oxidative Damage, Inflammation, and Gut Microbiota Disorder Read More »

Biomarkers for REM sleep behavior disorder in idiopathic
and narcoleptic patients

A-Synuclein, iRBD /

To search for discriminating biomarkers, 30 patients with idiopathic rapid-eyemovements sleep behavior disorder (iRBD) were compared with 17 patientswith RBD within narcolepsy type 1. Both groups underwent extensive examinations, including skin biopsy searching for phosphorylated a-synuclein depositsand whole-night video-polysomnography. Skin biopsy was positive for phosphorylated a-synuclein deposits in 86.7% of iRBD patients and in none

Biomarkers for REM sleep behavior disorder in idiopathic
and narcoleptic patients Read More »

Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson’s Disease Using Gait Parameters

A-Synuclein, iRBD, Parkinson's Disease, Pre-PD /

Gait parameters and a pretrained statistical model can robustly distinguish participants with iRBD from HCs and patients with PD. This could be used to screen subjects with future synucleinopathies in the general population and to identify a conversion threshold to PD. CLICK TO REVIEW

Classifying Idiopathic Rapid Eye Movement Sleep Behavior Disorder, Controls, and Mild Parkinson’s Disease Using Gait Parameters Read More »

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Butyrate, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Read More »

Identification of an early-stage Parkinson’s disease neuromarker using event-related potentials, brain network analytics and machine-learning

Biomarkers, Parkinson's Disease, Pre-PD /

This pilot study found that BNA can identify patients with early PD using an advanced analysis of ERPs. These results need to be validated in a larger PD patient sample and assessed for people with premotor phase of PD. CLICK TO REVIEW

Identification of an early-stage Parkinson’s disease neuromarker using event-related potentials, brain network analytics and machine-learning Read More »

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients

Butyrate, Constipation, Gut Microbiota, Parkinson's Disease, Short Chain Fatty Acids /

Background and Objectives: Short-chain fatty acids (SCFAs) are gut microbial metabolitesthat promote the disease process in a rodent model of Parkinson’s disease (PD), but fecallevels of SCFAs in PD patients are reduced. Simultaneous assessments of fecal and plasmaSCFA levels, and their inter-relationships with the PD disease process are scarce. We aimedto compare fecal and plasma

Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients Read More »

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation

Butyrate, Constipation, Pre-PD, Short Chain Fatty Acids /

A variety of opinions exist on the potential of probiotics to provide relief from chronic constipation with much focus placed on their mechanism of action and causes of heterogeneity in the results of different studies. We aimed to determine the efficacy and safety of ingesting Bifidobacterium bifidum (B. bifidum) CCFM16 for 28 days to relieve

A randomised, double-blind, placebo-controlled trial of Bifidobacterium bifidum CCFM16 for manipulation of gut microbiota and relief from chronic constipation Read More »

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

Autonmic nervous system, Biomarkers, Butyrate, Gut Dysbiosis, Gut Permeability / Leaky Gut, Parkinson's Disease, Short Chain Fatty Acids /

Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Read More »

Non-Motor Symptoms and Their Associated Factors in Parkinson’s Disease

Biomarkers, Constipation, Dreams, Non-Motor Symptoms, Orthostatic Hypotension /

Background: Parkinson’s disease is a common neurologic ailment that causes tremor and bradykinesia. The prevalenceof Parkinson’s disease is estimated to be 1–2 in 1000, affecting about 1% of the population over the age of 60 years. Theobjective of this study was to find the frequency of Non-Motor Symptoms in patients with Parkinson’s Disease (PD) andits

Non-Motor Symptoms and Their Associated Factors in Parkinson’s Disease Read More »